News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,740 Results
Type
Article (14272)
Company Profile (281)
Press Release (254187)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79544)
Career Advice (153)
Deals (13232)
Drug Delivery (35)
Drug Development (50466)
Employer Resources (31)
FDA (5728)
Job Trends (5139)
News (144459)
Policy (10033)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21681)
ALS (68)
Alzheimer's disease (850)
Antibody-drug conjugate (ADC) (108)
Approvals (5753)
Artificial intelligence (132)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (161)
Cancer (1515)
Cardiovascular disease (120)
Career advice (134)
Career pathing (2)
CAR-T (121)
Cell therapy (337)
Cervical cancer (9)
Clinical research (41156)
Collaboration (557)
Compensation (275)
Complete response letters (13)
COVID-19 (1034)
CRISPR (44)
C-suite (171)
Cystic fibrosis (77)
Data (1592)
Denatured (11)
Depression (32)
Diabetes (142)
Diagnostics (1302)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (91)
Earnings (30066)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48761)
Executive appointments (471)
FDA (6492)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (509)
Gene editing (102)
Generative AI (10)
Gene therapy (260)
GLP-1 (370)
Government (1084)
Grass and pollen (2)
Guidances (66)
Healthcare (6595)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (96)
Indications (20)
Infectious disease (1100)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7279)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (214)
Leadership (3)
Legal (1386)
Liver cancer (34)
Lung cancer (207)
Lymphoma (103)
Machine learning (5)
Management (7)
Manufacturing (147)
MASH (59)
Medical device (2602)
Medtech (2603)
Mergers & acquisitions (6291)
Metabolic disorders (402)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (71)
Neuropsychiatric disorders (25)
Neuroscience (1269)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (22)
Obesity (197)
Opinion (102)
Ovarian cancer (66)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (121)
Partnered (8)
Patents (135)
Patient recruitment (82)
Peanut (35)
People (25678)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14537)
Phase II (19151)
Phase III (12094)
Pipeline (915)
Policy (48)
Postmarket research (852)
Preclinical (6155)
Press Release (30)
Prostate cancer (63)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (296)
Real estate (1419)
Recruiting (12)
Regulatory (8675)
Reports (16)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (62)
Series A (99)
Series B (66)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1976)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (216)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Last 7 days (555)
Last 30 days (1714)
Last 365 days (19252)
2025 (6915)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27807)
2020 (23357)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17343)
Australia (2941)
California (4036)
Canada (1170)
China (372)
Colorado (152)
Connecticut (154)
Delaware (109)
Europe (37326)
Florida (491)
Georgia (121)
Idaho (16)
Illinois (238)
India (10)
Indiana (94)
Iowa (2)
Japan (78)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (492)
Massachusetts (3209)
Michigan (72)
Minnesota (150)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1001)
New Mexico (12)
New York (1081)
North Carolina (567)
North Dakota (5)
Northern California (1796)
Ohio (114)
Oklahoma (9)
Oregon (21)
Pennsylvania (762)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1553)
Tennessee (25)
Texas (468)
United States (13781)
Utah (56)
Virginia (83)
Washington D.C. (31)
Washington State (359)
Wisconsin (16)
268,740 Results for "eidos therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.
BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve all proposals related to BridgeBio’s acquisition of all of the outstanding shares of Eidos common stock that BridgeBio does not already own.
January 19, 2021
·
9 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Deals
BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.
BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own.
January 26, 2021
·
9 min read
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
Press Releases
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada
May 8, 2025
·
6 min read
Deals
BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger
BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, on the terms and subject to the conditions of their previously announced merger agreement, is expected to close on or about January 26, 2021.
January 13, 2021
·
12 min read
Deals
BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement
Agreement Brings BridgeBio’s Clinical Development and Commercial Development Infrastructureto Bear Upon Eidos’Acoramidis, Creating Anticipated Value for Patients with ATTR and Investors
October 5, 2020
·
16 min read
Press Releases
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
April 17, 2025
·
13 min read
Press Releases
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
April 15, 2025
·
7 min read
Business
Eidos Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an update on the company’s operations. “The completion of enrollment in our Phase 3 ATTRibute-CM clinical study marks the next milestone in the accelerated development of acoramidis for patients with transthyretin (TTR) amyloidosis (ATTR),” said Neil Kumar, PhD, chief executive officer of Eidos. “Sinc
October 29, 2020
·
18 min read
1 of 26,874
Next